We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+14.74%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$792M
AUM Growth
+$9.15M
Cap. Flow
-$28.5M
Cap. Flow %
-3.6%
Top 10 Hldgs %
65.85%
Holding
54
New
9
Increased
12
Reduced
17
Closed
8

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$65.8M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
ASND icon
Ascendis Pharma A/S
ASND
+$7.66M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.13M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$28.3M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$17.1M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$14.1M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Miscellaneous 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
51
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-125,800
Closed -$258K
TRIL
52
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-227,399
Closed -$1.4M
AVXS
53
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-225,370
Closed -$17.1M
1 2
3

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Avoro Capital Advisors held 54 positions worth $792M, up 1.2% from $783M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors withdrew a net $28.5M in Q2 2017, closing 8 positions and reducing 17 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $28.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avoro Capital Advisors opened a new position in Kite Pharma, Inc. worth $83.6M.

  • Avoro Capital Advisors's largest Q2 2017 buy was Kite Pharma, Inc.: 806,750 shares worth $83.6M.
  • Avoro Capital Advisors added most to Amicus Therapeutics in Q2 2017, an estimated $8.72M increase.
  • Avoro Capital Advisors's biggest Q2 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $30.3M.
  • Avoro Capital Advisors fully exited Seagen Inc. Common Stock in Q2 2017, selling an estimated $28.3M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $792M portfolio in Q2 2017.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q2 2017.
  • Avoro Capital Advisors's portfolio value rose 1.2% quarter-over-quarter to $792M.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.